Moyle G - Search Results

1

Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.

Dickinson L, Boffito M, Back D, Else L, von Hentig N, Davies G, Khoo S, Pozniak A, Moyle G, Aarons L. Dickinson L, et al. Among authors: moyle g. Antimicrob Agents Chemother. 2011 Jun;55(6):2775-82. doi: 10.1128/AAC.00887-10. Epub 2011 Mar 21. Antimicrob Agents Chemother. 2011. PMID: 21422211 Free PMC article.

2

Principles and practice of HIV-protease inhibitor pharmacoenhancement.

Moyle GJ, Back D. Moyle GJ, et al. HIV Med. 2001 Apr;2(2):105-13. doi: 10.1046/j.1468-1293.2001.00063.x. HIV Med. 2001. PMID: 11737387 Free article. Review.

3

Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000.

Scott P, Arnold E, Evans B, Pozniak A, Moyle G, Shahmenesh M, White D, Shirley J, Cane P, Pillay D. Scott P, et al. Among authors: moyle g. J Antimicrob Chemother. 2004 Mar;53(3):469-73. doi: 10.1093/jac/dkh102. Epub 2004 Jan 28. J Antimicrob Chemother. 2004. PMID: 14749345

4

Pharmacokinetic considerations for combining 2 protease inhibitors.

Boffito M, Moyle GJ. Boffito M, et al. AIDS Read. 2004 Mar;14(3):110-2, 115-6. AIDS Read. 2004. PMID: 15067999 Review. No abstract available.

5

Can we boost enough without ritonavir?

Boffito M, Moyle GJ. Boffito M, et al. AIDS Read. 2004 May;14(5):229-30, 233-5. AIDS Read. 2004. PMID: 15198081 Review. No abstract available.

6

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Ford J, et al. Among authors: moyle g. Antimicrob Agents Chemother. 2004 Jul;48(7):2388-93. doi: 10.1128/AAC.48.7.2388-2393.2004. Antimicrob Agents Chemother. 2004. PMID: 15215085 Free PMC article. Clinical Trial.

7

Unexpected drug interactions and adverse events with antiretroviral drugs.

Moyle G, Boffito M. Moyle G, et al. Lancet. 2004 Jul 3-9;364(9428):8-10. doi: 10.1016/S0140-6736(04)16608-7. Lancet. 2004. PMID: 15234836 No abstract available.

8

Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Mandalia S, Gazzard B, Pozniak A. Boffito M, et al. Among authors: moyle g. Antivir Ther. 2004 Jun;9(3):423-9. Antivir Ther. 2004. PMID: 15259905 Clinical Trial.

9

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL. Boffito M, et al. Among authors: moyle gj. AIDS. 2004 Jun 18;18(9):1291-7. doi: 10.1097/00002030-200406180-00007. AIDS. 2004. PMID: 15362661

10

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A. Boffito M, et al. Among authors: moyle g. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1376-84. doi: 10.1097/01.qai.0000136060.65716.1a. J Acquir Immune Defic Syndr. 2004. PMID: 15483467

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters